Amedisys’ (AMED) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Amedisys (NASDAQ:AMED – Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $100.00 target price on the health services provider’s stock. Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares […]